Prostate Cancer News and Research

RSS
Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Unveiling Progesterone's Impact on Cancer Immunosuppression

Unveiling Progesterone's Impact on Cancer Immunosuppression

AI Uncovers Cancer Drivers in Non-Coding DNA

AI Uncovers Cancer Drivers in Non-Coding DNA

Are Advances in AI Technology Transforming Immunohistochemistry Analysis in Pathology?

Are Advances in AI Technology Transforming Immunohistochemistry Analysis in Pathology?

Researchers Advance Single-Molecule DNA Sequencing Techniques

Researchers Advance Single-Molecule DNA Sequencing Techniques

Genomic Deletions Drive Development of Melanoma Drug Resistance

Genomic Deletions Drive Development of Melanoma Drug Resistance

Understanding Prostate Cancer Disparities Through Proteogenomics

Understanding Prostate Cancer Disparities Through Proteogenomics

Large Study Finds 187 New Genetic Variants Linked to Prostate Cancer

Large Study Finds 187 New Genetic Variants Linked to Prostate Cancer

Novel Activation Mechanism for First Identified Oncogene

Novel Activation Mechanism for First Identified Oncogene

Targeted MicroRNA-34a Therapy Shows Promise in Slowing Tumor Growth in Mice

Targeted MicroRNA-34a Therapy Shows Promise in Slowing Tumor Growth in Mice

New Insights Into How Cells Maintain Optimal Health

New Insights Into How Cells Maintain Optimal Health

New Findings May Provide Useful Therapeutic Approach for Treating Breast Cancer Patients

New Findings May Provide Useful Therapeutic Approach for Treating Breast Cancer Patients

Study Offers New Insights Into Neuroendocrine Transdifferentiation in Breast and Prostate Cancer Biology

Study Offers New Insights Into Neuroendocrine Transdifferentiation in Breast and Prostate Cancer Biology

New CAR T Strategy Offers a Dual-Targeting Mechanism to Fight Bone Metastatic Prostate Cancer

New CAR T Strategy Offers a Dual-Targeting Mechanism to Fight Bone Metastatic Prostate Cancer

Mirror-Image Versions of a Small Molecule Pave New Way for Cancer Drug Discovery

Mirror-Image Versions of a Small Molecule Pave New Way for Cancer Drug Discovery

High-Throughput Assay to Analyze the Effects of CAR-T Cells Using Image Cytometry

High-Throughput Assay to Analyze the Effects of CAR-T Cells Using Image Cytometry

Scientists Illuminate the Mechanism that Raises and Lowers PSMA Expression in Prostate Cancer

Scientists Illuminate the Mechanism that Raises and Lowers PSMA Expression in Prostate Cancer

Novel Genes Could Serve as Predictive Biomarkers for PARP Inhibitor Response in Prostate Cancer

Novel Genes Could Serve as Predictive Biomarkers for PARP Inhibitor Response in Prostate Cancer

New combination therapy regimen may reduce prostate cancer progression or death by 37%

New combination therapy regimen may reduce prostate cancer progression or death by 37%

First molecular images of olfaction sets the stage to create novel smells

First molecular images of olfaction sets the stage to create novel smells

Significance of large-scale genetic studies in men of African ancestry

Significance of large-scale genetic studies in men of African ancestry

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.